ATE422883T1 - Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden - Google Patents

Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden

Info

Publication number
ATE422883T1
ATE422883T1 AT03780642T AT03780642T ATE422883T1 AT E422883 T1 ATE422883 T1 AT E422883T1 AT 03780642 T AT03780642 T AT 03780642T AT 03780642 T AT03780642 T AT 03780642T AT E422883 T1 ATE422883 T1 AT E422883T1
Authority
AT
Austria
Prior art keywords
andropause
carnitines
prevent
diseases caused
treat diseases
Prior art date
Application number
AT03780642T
Other languages
English (en)
Inventor
Aleardo Koverech
Giorgio Cavallini
Giulio Biagiotti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE422883T1 publication Critical patent/ATE422883T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03780642T 2002-12-13 2003-11-20 Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden ATE422883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Publications (1)

Publication Number Publication Date
ATE422883T1 true ATE422883T1 (de) 2009-03-15

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03780642T ATE422883T1 (de) 2002-12-13 2003-11-20 Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden

Country Status (17)

Country Link
US (1) US7956091B2 (de)
EP (1) EP1569635B1 (de)
JP (1) JP4767542B2 (de)
KR (1) KR101039818B1 (de)
AT (1) ATE422883T1 (de)
AU (1) AU2003288739A1 (de)
CA (1) CA2507429C (de)
CY (1) CY1109051T1 (de)
DE (1) DE60326262D1 (de)
DK (1) DK1569635T3 (de)
ES (1) ES2322455T3 (de)
IT (1) ITRM20020620A1 (de)
MX (1) MXPA05006072A (de)
PL (1) PL211032B1 (de)
PT (1) PT1569635E (de)
SI (1) SI1569635T1 (de)
WO (1) WO2004054567A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
ATE437884T1 (de) 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (de) * 1994-05-12 1997-11-12 Hirohiko Kuratsune Acylcarnitin-enthaltende pharmazeutische Zusammensetzung
IT1290801B1 (it) 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
EP1399143B1 (de) * 2001-05-29 2006-11-15 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia

Also Published As

Publication number Publication date
CY1109051T1 (el) 2014-07-02
PT1569635E (pt) 2009-05-11
US20060135606A1 (en) 2006-06-22
KR20050084052A (ko) 2005-08-26
SI1569635T1 (sl) 2009-06-30
KR101039818B1 (ko) 2011-06-09
US7956091B2 (en) 2011-06-07
AU2003288739A1 (en) 2004-07-09
EP1569635B1 (de) 2009-02-18
ES2322455T3 (es) 2009-06-22
PL378418A1 (pl) 2006-04-03
PL211032B1 (pl) 2012-04-30
WO2004054567A1 (en) 2004-07-01
CA2507429A1 (en) 2004-07-01
ITRM20020620A1 (it) 2004-06-14
CA2507429C (en) 2012-09-04
DE60326262D1 (de) 2009-04-02
JP4767542B2 (ja) 2011-09-07
EP1569635A1 (de) 2005-09-07
DK1569635T3 (da) 2009-04-20
JP2006511531A (ja) 2006-04-06
MXPA05006072A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
BR0313185A (pt) Probióticos para funções neuromusculares intestinais
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
BRPI0410131A (pt) suplemento dietético para uso no tratamento e/ou inibição de úlceras do trato digestivo em equinos e outros animais e seu método
TW200510308A (en) Isophthalic acid derivatives
AR021172A1 (es) Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide
HK1078460A1 (en) Use of l-carnitine, actyl l-carnitine and propionyl l-carnitine in the manufacture of a combined medicament for the treatment of oligoasthenoteratospermia
HK1109029A1 (en) Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE456950T1 (de) Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion
ATE259778T1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE602006021594D1 (de) Verbindung zur prävention und behandlung von links
HUP0204467A2 (hu) Propinoil-l-karnitin és koenzim Q10-et tartalmazó készítmény érrendszeri betegségek megelőzésére és/vagy kezelésére
ATE419847T1 (de) Verwendung von acetyl-l-carinitin zur behandlung des fibromyalgischen syndroms
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung
DE602006002126D1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
CN1223128A (zh) 降压减肥茶
RU2002123989A (ru) Способ лечения хронических заболеваний печени с проявлениями нарушений микроэкологии кишечника
王建萍 et al. TREATMENT OF 120 CASES OF SOFT-TISSUE INJURY OF THE SHOULDER-BACK REGION WIT H FLOATING NEEDLE
RU2007107532A (ru) Способ лечения нарушений первичного гемостаза у лиц с метаболическим синдромом
RU2002132905A (ru) Способ лечения атопического хейлита у детей
CN103798770A (zh) 一种治疗胃溃疡的食疗方法
RU2009112931A (ru) Способ лечения больных с переломом нижней челюсти
JP2015167560A (ja) 和漢方組成食品

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569635

Country of ref document: EP